Atwater Malick’s AbbVie ABBV Stock Holding History

Atwater Malick’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$872K	Sell	3,335 -7	-0.2%	-$1.8K	0.19%	59
2026 Q2	$841K	Buy	3,342 +315	+10%	+$67.8K	0.18%	61
2026 Q1	$658K	Sell	3,027 -210	-6%	-$46.6K	0.18%	51
2025 Q4	$740K	Buy	3,237 +391	+14%	+$89.1K	0.2%	45
2025 Q3	$659K	Hold	2,846	–	–	0.19%	48
2025 Q2	$528K	Buy	2,846 +135	+5%	+$25.1K	0.17%	54
2025 Q1	$568K	Sell	2,711 -13	-0.5%	-$2.53K	0.19%	50
2024 Q4	$484K	Hold	2,724	–	–	0.16%	49
2024 Q3	$538K	Sell	2,724 -40	-1%	-$7.46K	0.17%	51
2024 Q2	$474K	Hold	2,764	–	–	0.16%	53
2024 Q1	$503K	Buy	2,764 +1,095	+66%	+$189K	0.18%	56
2023 Q4	$259K	Sell	1,669 -468	-22%	-$68.2K	0.1%	62
2023 Q3	$319K	Hold	2,137	–	–	0.14%	55
2023 Q2	$288K	Buy	2,137 +510	+31%	+$74.8K	0.12%	59
2023 Q1	$259K	Buy	1,627 +24	+1%	+$3.67K	0.12%	55
2022 Q4	$259K	Buy	+1,603	New	+$246K	0.13%	51
2019 Q4	–	Sell	-686	Closed	-$52K	–	39
2019 Q3	$52K	Buy	+686	New	+$47K	0.04%	74

Other funds holding ABBV

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Cardano Risk Management Rotterdam, Netherlands $18.2B AUM 38.97% 1-Year Est. Return

Hamlin Capital Management New York $4.04B AUM 11.59% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Ferguson Wellman Capital Management Portland, Oregon $8.38B AUM 25.07% 1-Year Est. Return

ABN AMRO Investment Solutions Paris Cedex 008 $13.2B AUM 30.55% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

Atwater Malick's ABBV Position: Q3 2026 in Review

Atwater Malick reduced its AbbVie (ABBV) stake by 0.21% in Q3 2026, selling an estimated $1.8K and leaving 3,335 shares worth $872K. The position accounts for 0.19% of the portfolio, ranked #59.

Atwater Malick first reported a position in ABBV in Q3 2019 and has held it in 17 quarters since. 1,159 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

Atwater Malick held 3,335 shares of AbbVie worth $872K as of Q3 2026.
Atwater Malick sold 7 AbbVie shares in Q3 2026, an estimated $1.8K.
AbbVie made up 0.19% of Atwater Malick's portfolio in Q3 2026, its #59 holding.
Atwater Malick first reported a position in AbbVie in Q3 2019 and has held it in 17 quarters since.
1,159 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Atwater Malick's 13F filing for Q3 2026, filed 15 Oct 2026.